Want to see ASPI full AI Analyst Report?
Top Page
ASP Isotopes, Inc.
(NASDAQ:ASPI)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.00
▲(31.09% Upside)
Action:Reiterated
Date:01/31/26
The score is held back primarily by weak financial quality (losses and high leverage) despite strong revenue growth. Technicals are neutral-to-slightly constructive near-term but weaker longer-term, and valuation remains challenging due to negative earnings and no dividend yield support. Earnings-call and corporate updates add some upside optionality via new facilities/contracts and recent strategic actions, but execution and guidance uncertainty keep the overall score below average.
Positive Factors
Revenue Growth & Gross Margin
Sustained high revenue growth coupled with a healthy gross margin signals durable end-market demand and initial pricing power for core isotope products. This supports scalable gross profits as production capacity ramps, enabling reinvestment in facilities and R&D to capture long-term market opportunities.
Negative Factors
Persistent Unprofitability
Material negative net and EBIT margins indicate core operations are not yet generating sustainable profits. Continued losses constrain self-funded growth, raise reliance on external financing, and heighten dilution or refinancing risk while the company scales capital-intensive enrichment facilities.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Gross Margin
Sustained high revenue growth coupled with a healthy gross margin signals durable end-market demand and initial pricing power for core isotope products. This supports scalable gross profits as production capacity ramps, enabling reinvestment in facilities and R&D to capture long-term market opportunities.
Read all positive factors
ASP Isotopes, Inc. (ASPI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$503.61M
Dividend YieldN/A
Average Volume (3M)5.64M
Price to Earnings (P/E)―
Beta (1Y)2.03
Revenue Growth511.23%
EPS Growth-240.64%
CountryUS
Employees271
SectorBasic Materials
Sector Strength58
IndustryChemicals
Share Statistics
EPS (TTM)N/A
Shares Outstanding125,903,450
10 Day Avg. Volume6,314,928
30 Day Avg. Volume5,636,470
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.18
Price to Sales (P/S)18.62
P/FCF Ratio-9.36
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue22.64
Enterprise Value/Gross Profit128.49
Enterprise Value/Ebitda-3.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ASP Isotopes, Inc. Business Overview & Revenue Model
Company Description
ASP Isotopes, Inc. (ASPI) is a company focused on the production and supply of isotopes for use in healthcare (including medical diagnostics and potential therapeutics), industrial applications, and other specialized markets that require isotopica...
How the Company Makes Money
null...
ASP Isotopes, Inc. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
40
Negative
Cash Flow
50
Neutral
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.93M | 23.85M | 4.14M | 433.03K | 0.00 | 0.00 |
| Gross Profit | 4.74M | 3.40M | 1.60M | 138.97K | 0.00 | -19.38K |
| EBITDA | -170.61M | -157.07M | -31.58M | -16.14M | -4.87M | -2.59M |
| Net Income | -173.52M | -175.09M | -32.33M | -16.29M | -4.95M | -2.61M |
Balance Sheet | ||||||
| Total Assets | 587.67M | 512.88M | 94.35M | 30.19M | 12.50M | 7.14M |
| Cash, Cash Equivalents and Short-Term Investments | 290.52M | 333.31M | 61.89M | 7.91M | 2.39M | 2.95M |
| Total Debt | 261.84M | 215.96M | 37.75M | 2.14M | 822.20K | 926.60K |
| Total Liabilities | 288.65M | 249.98M | 43.18M | 11.36M | 2.68M | 1.14M |
| Stockholders Equity | 289.00M | 204.15M | 47.90M | 16.30M | 9.82M | 6.00M |
Cash Flow | ||||||
| Free Cash Flow | -65.80M | -47.43M | -28.07M | -7.74M | -7.41M | -3.57M |
| Operating Cash Flow | -52.37M | -37.78M | -16.70M | -5.41M | -2.94M | -577.69K |
| Investing Cash Flow | -205.62M | -90.00M | -11.37M | -2.45M | -4.47M | -2.99M |
| Financing Cash Flow | 414.99M | 350.80M | 82.53M | 13.39M | 6.64M | 6.50M |
ASP Isotopes, Inc. Technical Analysis
Negative
5.34
Price Trends
5.62
Negative
5.36
Negative
6.08
Negative
Market Momentum
-0.40
Negative
41.90
Neutral
70.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASPI, the sentiment is Negative. The current price of 5.34 is above the 20-day moving average (MA) of 4.14, below the 50-day MA of 5.62, and below the 200-day MA of 6.08, indicating a bearish trend. The MACD of -0.40 indicates Negative momentum. The RSI at 41.90 is Neutral, neither overbought nor oversold. The STOCH value of 70.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASPI.
ASP Isotopes, Inc. Risk Analysis
ASP Isotopes, Inc. disclosed 127 risk factors in its most recent earnings report. ASP Isotopes, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ASP Isotopes, Inc. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | $783.33M | 21.80 | 6.98% | ― | 22.12% | ― | |
52 Neutral | $603.57M | -1.27 | -32.62% | ― | -10.59% | -571.99% | |
49 Neutral | $503.61M | -1.93 | -117.16% | ― | 511.23% | -240.64% | |
49 Neutral | $931.62M | -2.00 | -31.25% | 3.21% | -4.02% | -206.93% | |
48 Neutral | $540.80M | 51.44 | 1.28% | 3.04% | -0.63% | -87.72% | |
42 Neutral | $850.54M | -0.69 | 142.56% | ― | -13.10% | -0.68% |
* Basic Materials Sector Average
ASPI
ASP Isotopes, Inc.
4.10
-5.58
-57.64%
BAK
Braskem SA
2.33
-0.71
-23.36%
LXU
Lsb Industries
9.69
2.29
30.95%
TROX
TRONOX
6.95
3.86
124.85%
RYAM
Rayonier Advanced Materials
9.16
4.79
109.61%
ASIX
AdvanSix
20.14
2.26
12.65%
ASP Isotopes, Inc. Corporate Events
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
ASP Isotopes Announces Capital Markets Day Amid Strategic Review
Positive
Jul 28, 2026
On July 28, 2026, ASP Isotopes announced it will hold a Capital Markets Day in London on Tuesday, September 8, 2026, with in-person attendance by invitation and public access via live webcast and replay. Management plans to present a detailed upda...
Business Operations and Strategy
ASP Isotopes Unit Signs Nuclear Fuel Research Deal
Positive
Jul 21, 2026
On July 21, 2026, Quantum Leap Energy LLC, a subsidiary of ASP Isotopes Inc., signed a research agreement with the Texas AM Engineering Experiment Station to advance and de‑risk commercial production of high‑purity uranium hexafluoride...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
ASP Isotopes refocuses operations after Skyline deconsolidation
Positive
Jul 17, 2026
ASP Isotopes Inc. has retrospectively recast certain financial information in its 2025 annual report to reflect the construction services business, including Skyline Builders Group Holding Limited, as discontinued operations after completing Skyli...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
ASP Isotopes Plans Merger, Nasdaq Listing for Noble Africa
Positive
Jun 25, 2026
On June 25, 2026, ASP Isotopes and ENDRA Life Sciences announced a proposed merger of ASP’s wholly owned subsidiary Noble Africa with an ENDRA subsidiary, with Noble Africa to remain as the surviving entity and the combined company to apply ...
Business Operations and StrategyProduct-Related Announcements
ASP Isotopes Restarts Upgraded Silicon-28 Enrichment Facility
Positive
May 26, 2026
ASP Isotopes Inc., an advanced materials company specializing in isotope enrichment technologies for nuclear medicine, next-generation semiconductors and nuclear energy, operates light-isotope enrichment facilities in Pretoria, South Africa. Its p...
Business Operations and StrategyRegulatory Filings and Compliance
ASP Isotopes Issues New Investor Presentation Under Reg FD
Neutral
May 20, 2026
On May 20, 2026, ASP Isotopes Inc. released its latest investor presentation, making it available on its corporate website and clarifying that the material is provided as of that date and is not intended to be treated as filed with the U.S. Securi...
Business Operations and Strategy
ASP Isotopes signs HALEU supply MOU for reactors
Positive
May 11, 2026
On May 11, 2026, ASP Isotopes’ subsidiary Quantum Leap Energy announced a non-binding memorandum of understanding with a European nuclear technology company focused on advanced reactor development. The agreement centers on assessing a long-t...
Business Operations and StrategyExecutive/Board Changes
ASP Isotopes Subsidiary Adds Expert to Advisory Board
Positive
May 6, 2026
On May 6, 2026, ASP Isotopes announced that its wholly owned subsidiary Quantum Leap Energy appointed technology commercialization specialist Dr. Peter S. Fiske to QLE’s Strategic Advisory Board. His background spans leadership roles at the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.